JAHA: The relationship between common drugs and cerebral hemorrhage

For a variety of adaptations, prescriptions often include antiplates, anticoagulants, and statins.
link between these drugs and the risk of cerebral hemorrhage (ICH) and cerebral micro-bleeding (CMBs) is not clear.
, researchers conducted a retrospective analysis of community atherosclerosis risk (ARIC) studies that recruited and followed subjects from four communities in the United States between 1987 and 1989.
from 2011 to 2013, the researchers performed an MRI on the subgroup (N-1942) and a CMB assessment.
the use of any antiplate plateasts, anticoagulants, or statins in subsequent follow-up visits.
To determine the ICH and CMB risks posed by drug use, the researchers built the Logistic model and the Cox proportional risk model, respectively, to adjust the propensity to take the drug, the use of other drugs at the same time, and cognitive, genetic and imaging data.
20 years of follow-up, 130 out of 15,719 patients experienced ICH.
compared to non-users, the corrected ICH risk was significantly lower among participants who received antiplate plateplate therapy prior to ICH (risk ratio of 0.53; 95% CI was 0.30-0.92).
, statin users had a much lower ICH risk than non-users (corrected HR was 0.13; 95% CI was 0.05-0.34).
in the adjusted model, CMB was not associated with the use of antiplate plateplates, anticoagulants, or statins.
In this study, based on the U.S. community, the use of antiplateplates and statins was associated with a lower ICH risk, while there was no correlation between CMB and antiplates, anticoagulants, and statins.
further research is needed to understand the different roles of these drugs in cerebral micro-bleeding and haemorrhage.